Dr. Sweis is a physician-scientist working to identify and circumvent mechanisms of resistance to cancer immunotherapies. His laboratory research is focused on modulating the tumor microenvironment to facilitate anti-tumor immune responses, using mouse models of bladder and skin cancers. In the clinic, he uses his expertise in developmental therapeutics and clinical pharmacology to investigate biomarkers and novel therapeutic strategies to improve immunotherapy efficacy in patients.
PKCd Germline Variants and Genetic Deletion in Mice Augment Antitumor Immunity through Regulation of Myeloid Cells.
PKCd Germline Variants and Genetic Deletion in Mice Augment Antitumor Immunity through Regulation of Myeloid Cells. Cancer Immunol Res. 2025 Apr 02; 13(4):547-559.
PMID: 39808445
Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas.
Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas. Clin Cancer Res. 2025 Apr 01; 31(7):1233-1242.
PMID: 39846804
A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer.
A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer. Clin Cancer Res. 2025 Jan 17; 31(2):299-307.
PMID: 39576210
High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltration.
High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltration. Breast Cancer Res Treat. 2025 Feb; 209(3):563-572.
PMID: 39579248
A phase II open label, randomized clinical trial of atezolizumab with or without human recombinant IL-7 (CYT107) in advanced urothelial cancer.
A phase II open label, randomized clinical trial of atezolizumab with or without human recombinant IL-7 (CYT107) in advanced urothelial cancer. Clin Cancer Res. 2024 Nov 22.
PMID: 39576210
Primary site stereotactic ablative body radiotherapy in localized, recurrent, and metastatic renal cell carcinoma.
Primary site stereotactic ablative body radiotherapy in localized, recurrent, and metastatic renal cell carcinoma. Clin Transl Radiat Oncol. 2024 Nov; 49:100879.
PMID: 39529961
Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical Trial.
Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical Trial. JAMA Oncol. 2024 Nov; 10(11):1565-1570.
PMID: 39298147
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma.
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2025 Jan 02; 392(1):45-55.
PMID: 39282902
STING activators in cancer care.
STING activators in cancer care. Clin Adv Hematol Oncol. 2024 Sep; 22(7):331-333.
PMID: 39110661
Agent-Based Modeling of Virtual Tumors Reveals the Critical Influence of Microenvironmental Complexity on Immunotherapy Efficacy.
Agent-Based Modeling of Virtual Tumors Reveals the Critical Influence of Microenvironmental Complexity on Immunotherapy Efficacy. Cancers (Basel). 2024 Aug 23; 16(17).
PMID: 39272799